Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Lam M, Lum C, Latham S, et al. Refractory metastatic colorectal cancer: current challenges and future prospects. Cancer Manag Res. 2020;12:5819–5830. doi: 10.2147/CMAR.S213236
   PubMed Web of Science ®Google Scholar
• Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89–103. doi: 10.5114/pg.2018.81072
   PubMed Web of Science ®Google Scholar
• Byrne M, Saif MW. Selecting treatment options in refractory metastatic colorectal cancer. Onco Targets Ther. 2019;12:2271–2278. doi: 10.2147/OTT.S194605
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37. doi: 10.1200/JCO.2004.05.113
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12. doi: 10.1016/S0140-6736(12)61900-X
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909–19. doi: 10.1056/NEJMoa1414325
   PubMed Web of Science ®Google Scholar
• Prager GW, Taieb J, Fakih M, et al. Trifluridine–tipiracil and Bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023;388(18):1657–1667. doi: 10.1056/NEJMoa2214963
   PubMed Web of Science ®Google Scholar
• Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69 Suppl 3(Suppl. 3):4–10. doi: 10.1159/000088478
   PubMedGoogle Scholar
• Ghalehbandi S, Yuzugulen J, Pranjol MZI, et al. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur J Pharmacol. 2023;949:175586. doi: 10.1016/j.ejphar.2023.175586
   PubMed Web of Science ®Google Scholar
• Zhang Y, Brekken RA. Direct and indirect regulation of the tumor immune microenvironment by VEGF. J Leukocyte Biol. 2022;111(6):1269–1286. doi: 10.1002/JLB.5RU0222-082R
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. doi: 10.1093/annonc/mdw235
   PubMed Web of Science ®Google Scholar
• Bhargava P, Robinson MO. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep. 2011;13(2):103–11. doi: 10.1007/s11912-011-0154-3
   PubMed Web of Science ®Google Scholar
• Sun Q, Zhou J, Zhang Z, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635–45. doi: 10.4161/15384047.2014.964087
   PubMed Web of Science ®Google Scholar
• Information NCfB: PubChem substance record for SID 328083528, fruquintinib, source: IUPHAR/BPS guide to pharmacology. 2024 [cited 2024 Jan 16].
   Google Scholar
• Gu Y, Wang J, Li K, et al. Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. Cancer Chemother Pharmacol. 2014;74(1):95–115. doi: 10.1007/s00280-014-2471-3
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Schelman W, Ukrainskyj S, et al. Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States. Invest New Drugs. 2023;41(6):851–860. doi: 10.1007/s10637-023-01395-y
   PubMed Web of Science ®Google Scholar
• Zhou S, Shao F, Xu Z, et al. A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [(14)C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers. Cancer Chemother Pharmacol. 2017;80(3):563–573. doi: 10.1007/s00280-017-3394-6
   PubMed Web of Science ®Google Scholar
• Cao J, Zhang J, Peng W, et al. A phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;78(2):259–69. doi: 10.1007/s00280-016-3069-8
   PubMed Web of Science ®Google Scholar
• Xu RH, Li J, Bai Y, et al. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. 2017;10(1):22. doi: 10.1186/s13045-016-0384-9
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with Previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018;319:2486–2496. doi: 10.1001/jama.2018.7855
   PubMed Web of Science ®Google Scholar
• Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41–53. doi: 10.1016/S0140-6736(23)00772-9
   PubMed Web of Science ®Google Scholar
• Li J, Guo W, Bai Y, et al. Safety profile and adverse events of special interest for fruquintinib in Chinese patients with Previously treated metastatic colorectal cancer: analysis of the phase 3 FRESCO trial. Adv Ther. 2020;37(11):4585–4598. doi: 10.1007/s12325-020-01477-w
   PubMed Web of Science ®Google Scholar
• Miller KK, Gorcey L, BN M: Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787–794. doi: 10.1016/j.jaad.2014.03.019
   PubMed Web of Science ®Google Scholar
• Shou L, Chen J, Shao T, et al. Clinical characteristics, treatment outcomes, and prognosis in patients with MKIs-associated hand-foot skin reaction: a retrospective study. Support Care Cancer. 2023;31(7):375. doi: 10.1007/s00520-023-07830-3
   PubMed Web of Science ®Google Scholar
• Jatoi A, Ou FS, Ahn DH, et al. Preemptive versus reactive topical clobetasol for regorafenib-induced hand-foot reactions: a preplanned analysis of the ReDOS trial. Oncology. 2021;26(7):610–618. doi: 10.1002/onco.13730
   Google Scholar
• Santhosh A, Batra A, Kumar a, et al.: Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of hand-foot syndrome in patients receiving capecitabine. J Clin Oncol. 2023;41(16_suppl):12005–12005. doi: 10.1200/JCO.2023.41.16_suppl.12005
   Google Scholar
• Anderson R, Jatoi A, Robert C, et al. Search for Evidence-Based Approaches for the prevention and palliation of hand–foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncology. 2009;14(3):291–302. doi: 10.1634/theoncologist.2008-0237
   Google Scholar
• McLellan B, Ciardiello F, Lacouture ME, et al. Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol. 2015;26(10):2017–2026. doi: 10.1093/annonc/mdv244
   PubMed Web of Science ®Google Scholar
• Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Supplements. 2013;11(2):172–191. doi: 10.1016/j.ejcsup.2013.07.016
   PubMedGoogle Scholar
• Camarda N, Travers R, Yang VK, et al. VEGF receptor inhibitor-induced hypertension: emerging mechanisms and clinical implications. Curr Oncol Rep. 2022;24(4):463–474. doi: 10.1007/s11912-022-01224-0
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2023;41(21):3663–3669. doi: 10.1200/JCO.22.02760
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42. doi: 10.1056/NEJMoa032691
   PubMed Web of Science ®Google Scholar
• Zou J, Wang Y, Xu J, et al. A retrospective study of Trifluridine/Tipiracil with fruquintinib in patients with chemorefractory metastatic colorectal cancer. J Clin Med. 2023;13(1):2023. doi: 10.3390/jcm13010057
   Web of Science ®Google Scholar
• Li Q, Cheng X, Zhou C, et al. Fruquintinib enhances the antitumor immune responses of anti-programmed death receptor-1 in colorectal cancer. Front Oncol. 2022;12:841977. doi: 10.3389/fonc.2022.841977
   PubMed Web of Science ®Google Scholar
• Ma S, Chen R, Duan L, et al. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study. J Gastrointest Oncol. 2023;14(2):1052–1063. doi: 10.21037/jgo-23-108
   PubMed Web of Science ®Google Scholar
• Yang X, Yin X, Qu X, et al. Efficacy, safety, and predictors of fruquintinib plus anti-programmed death receptor-1 (PD-1) antibody in refractory microsatellite stable metastatic colorectal cancer in a real-world setting: a retrospective cohort study. J Gastrointest Oncol. 2023;14(6):2425–2435. doi: 10.21037/jgo-23-931
   PubMed Web of Science ®Google Scholar
• Li L, Wang T, Wu Z, et al. Fruquintinib in combination with sintilimab or TAS-102 as third-line or above treatment in patients with metastatic colorectal cancer: a real-world study. Transl Cancer Res. 2023;12(11):3034–3044. doi: 10.21037/tcr-23-867
   PubMed Web of Science ®Google Scholar